Merck Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology
– Patent covers paired Cas9 nickase technology to reduce off-target effects, advance gene therapy and research – Expands company’s foundational CRISPR cutting and integration IP necessary to correct genetic defects…